The present randomized controlled clinical trial was undertaken to evaluate the clinical efficacy of Shulaghna Saptak Vati in the management of post-operative pain following open haemorrhoidectomy and to compare its efficacy with Tab. Diclofenac sodium.

Based on the observations, statistical analysis, and clinical outcomes, both Shulaghna Saptak Vati and Tab. Diclofenac sodium were found to be effective in reducing post-operative pain following open haemorrhoidectomy. Within-group analysis demonstrated a statistically highly significant reduction in pain scores in both groups throughout the seven-day treatment period.

Comparative analysis revealed that patients treated with Shulaghna Saptak Vati experienced significantly greater pain relief during the early post-operative period, particularly from the second to the fifth post-operative day. The trial drug also demonstrated significantly lower cumulative pain scores, lower pain area under the curve (AUC), and earlier achievement of a sustained pain-free state when compared with Tab. Diclofenac sodium. Although complete pain relief was achieved in both groups by the seventh post-operative day, recovery was faster and the overall pain burden was significantly lower in patients receiving Shulaghna Saptak Vati. Thus the null hypothesis is rejected and alternate hypothesis is accepted that is Shulaghna saptak Vati is more effective than tab diclofenac sodium in post operative pain management after open heamorrhoidectomy

The favourable outcome observed with Shulaghna Saptak Vati may be attributed to the synergistic actions of its constituent drugs, which possess Vedanahara, Shothahara, Vranaropana, antioxidant, and anti-inflammatory properties. These combined actions not only alleviate post-operative pain but also support the physiological process of wound healing, thereby facilitating early recovery following open haemorrhoidectomy.

Diclofenac sodium, the standard comparator used in the present study, also produced highly significant analgesia through inhibition of cyclooxygenase enzymes and suppression of prostaglandin synthesis. However, its therapeutic effect is primarily limited to symptomatic pain relief, whereas Shulaghna Saptak Vati appears to provide a broader therapeutic effect by reducing inflammation and supporting tissue healing in addition to its analgesic action.

No serious adverse drug reactions or treatment-related complications attributable to Shulaghna Saptak Vati were observed during the study period, indicating that the formulation was safe and well tolerated.

Therefore, within the limitations of the present study, it can be concluded that Shulaghna Saptak Vati is an effective, safe, and clinically superior Ayurvedic formulation for the management of post-operative pain following open haemorrhoidectomy. The formulation provided earlier pain relief, reduced the cumulative pain burden, shortened the time required to achieve a sustained pain-free state, and improved overall post-operative recovery when compared with Tab. Diclofenac sodium.